Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 136

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 136
---
 our President and Chief Executive Officer, Steven King. If we were to lose his services, including through death
or disability, our ability to continue to execute our business plan would be materially impaired. We do not maintain “key person”
insurance for any of our executives or other employees. The Company has not entered into an employment agreement with Mr. King, or any
other officer of the Company.

If we are able to raise sufficient capital and potentially
license or acquire new technologies, then recruiting and retaining qualified scientific, clinical, regulatory, and manufacturing personnel
is critical to our success. We also may experience competition for the hiring of scientific and clinical personnel from universities and
research institutions. In addition, we have historically relied on consultants and advisors, including scientific and clinical advisors,
to assist us in product manufacturing, preclinical development, clinical development, regulatory strategy, and commercial strategy. Our
consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with
other entities that may limit their availability to provide services to us. If we are unable to attract and retain high quality personnel,
our ability to pursue our development strategy will be limited.

If we successfully identify new product candidates and license those
rights, then we expect to expand our research and development function, as well as our corporate operations, and as a result, we may encounter
difficulties in managing our growth, which could disrupt our operations. 

If we are able to raise sufficient capital and potentially
license or acquire new technologies, we would expect to experience significant growth in the number of our employees and the scope of
our operations, particularly in the areas of product manufacturing, preclinical research, clinical development, and regulatory affairs,
as capital resources become available. To manage our anticipated future growth, we must also implement and improve our managerial, operational
and financial systems, identify new facilities and continue to recruit and train additional qualified personnel. Due to our limited financial
resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel.
The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability
to manage growth could delay the execution of our business plans or disrupt our operations.

We may face risks related to securities litigation
that could result in significant legal expenses and settlement or damage awards.

We may in the future become subject to claims and
litigation alleging violations of the securities laws or other related claims, which could harm our business and require